0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Theralink Technologies
Its shares trade under the ticker THER. It has been listed since 23 April 2007. In the fiscal year to 30 September 2023, it reported revenue of $606,796 and a net loss of $30.9m. At that date it held total assets of $2.8m and shareholders' equity of −$38.1m.
Theralink Technologies, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. The company is headquartered in Baton Rouge, Louisiana. The company went IPO on 2007-04-23. The Company, through its phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. In addition to the Company’s first assay for advanced breast cancer, the Company is working on a second assay, which is pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, pancreatic, liver, head and neck, colorectal, lung, and prostate, among others. The company provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration (FDA)-approved and investigational drug treatments. The Company’s applications are across multiple cancer types, including but not limited to, breast, non-small cell lung, colorectal and pancreatic.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Apr 2007
- Employees
- 19
- Website
- oncbiomune.com ↗
Leadership
Pay as last reported
- Mr. Jeffrey BuschChairman of the Board, since 2020
- Ms. Faith ZaslavskyPresident, Chief Executive Officer, Chief Operating Officer$330,512
- Mr. Andrew KucharchukChief Financial Officer, Director, since 2015$122,613
- Dr. Michael RuxinChief Medical Officer, Director, since 2020$1.2m
- Ms. Yvonne ForsIndependent Director
- Ms. Danica HolleyIndependent Director
- Dr. Matthew SchwartzIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Theralink Technologies Inc employs 19 full-time employees in Baton Rouge, Louisiana.
- Theralink Reverse Phase Protein Array assays provide precision oncology data for multiple cancer types.
- The company's phosphoprotein and protein biomarker platform targets advanced breast cancer and pan-tumor solid tumors.
Weaknesses
- Theralink Technologies Inc has only 19 employees, limiting its operational capacity.
- The company's IPO on 23 April 2007 may indicate limited market traction.
- Theralink's focus on clinical-stage biopharmaceuticals requires significant capital investment.
Opportunities
- Theralink's pan-tumor assay for solid tumors across ovarian, endometrial, and pancreatic cancers presents growth potential.
- The company's LDTs can assist FDA-approved and investigational drug treatments in oncology.
- Theralink's applications across breast, non-small cell lung, and colorectal cancer types offer market expansion.
Threats
- Theralink's clinical-stage development faces regulatory hurdles from the FDA.
- The biopharmaceutical industry requires substantial capital, which may strain the company's resources.
- Competition in cancer immunotherapy could impact Theralink's market position.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.